Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

Fig. 4

Association of ETP changes with albuminuria stages and changes in eGFR. a Compared to patients with normal to mildly elevated albuminuria, an increase in P-ETP (ΔP-ETP) was observed in patients with moderately elevated, which further increased in patients with severely elevated albuminuria. b No change in U-ETP (ΔU-ETP) levels were observed between patients stratified by albuminuria status, but levels were significantly higher in patients treated with canagliflozin. c Whereas there was a significant weak negative correlation between the change in P-ETP and eGFR over the study (rho = − 0.24, p < 0.0001), a significant very weak positive correlation was observed for (d) U-ETP (rho = 0.11, p < 0.0001). For graph (a) and (b), median and [95% CI] is plotted for all patients combined (), and stratified into normal to mildly (), moderately (), and severely elevated albuminuria ()

Back to article page